H. Michael Shepard (born 1949) is an American cancer researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award, which he shared with Dennis Slamon and Axel Ullrich for their development of Herceptin[1]
Shepherd holds a bachelor's degree from the University of California, Davis, and a Ph.D. from Indiana University. Dr. Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University. His introduction to biotechnology came when he joined Genentech in 1980. Following Genentech, he has been a Founder or Principal in several biotech companies. These include Canji, Inc., NewBiotics, Receptor Biologix, and Halozyme.
Development of Herceptinedit
Following Ullrich's characterization of the HER2 protooncogene, Shepard collaborated with Ullrich and Slamon to explore possible links to breast cancer. Slamon discovered, along with other colleagues in the field, that HER2 overexpression in breast cancer predicts shorter survival. However, a lot of proteins are overexpressed in cancer cells and correlate with shorter survival. Therefore, the remaining question was: Is the overexpression of HER2 a significant driver in tumor progression and how does this work? Shepard and Hudziak discovered that too much HER2 made tumor cells grow better. Then made a key discovery about how HER2 can cause resistance to immune cell killing of tumor cells. Overexpression of HER2 makes cells resistant to killing by macrophages, which are the first line of defense against cancer. This work was done in collaboration with Dr. Hans Schreiber at the University of Chicago. Shepard and colleagues at Genentech (Paul Carter, Gail Lewis) then invented Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and developed it into a life-saving therapy for women with breast cancer. The innovation reduces the risk of recurrence and extends survival time for patients with metastatic as well as early-stage disease. Every year, more than 50,000 women in the US are diagnosed with the type of breast cancer that the drug attacks, and over 2.3 million individuals have received the treatment since it became available.
Other activityedit
Shepard has made seminal contributions to gene therapy of cancer, to tumor suppressor gene targeted small molecule therapeutics, and to drugs which target the tumor extracellular matrix. He continues his work, now expanding successful treatment paradigms used in cancer to approach inflammatory and autoimmune diseases. Shepard also consults for biopharma companies on how to develop meaningful biomarkers that will speed drug development. Education is another of Dr. Shepard's passions, and he gives lectures meant to teach, stimulate, excite and give hope to interested scientists and students, and to cancer patients who need to more about how the disease works. Dr. Shepard has co-authored many peer-reviewed publications and patents.
Patentsedit
U.S. patent 7,138,388 — Methods to treat autoimmune and inflammatory conditions
U.S. patent 7,105,156 — Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
U.S. patent 6,946,259 — Compositions and methods for treating cells having double minute DNA
U.S. patent 6,683,061 — Enzyme catalyzed therapeutic activation
U.S. patent 6,551,585 — Use of tumor necrosis factor as an adjuvant
U.S. patent 6,495,553 — Methods and compositions for overcoming resistance to biologic and chemotherapy
U.S. patent 6,399,063 — Monoclonal antibodies directed to the HER2 receptor
U.S. patent 6,387,371 — Monoclonal antibodies directed to the HER2 receptor
U.S. patent 6,348,352 — Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
U.S. patent 6,339,151 — Enzyme catalyzed therapeutic agents
U.S. patent 6,333,169 — HER2 extracellular domain
U.S. patent 6,331,524 — Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
U.S. patent 6,245,750 — Enzyme catalyzed therapeutic agents
U.S. patent 6,165,464 — Monoclonal antibodies directed to the HER2 receptor
U.S. patent 6,159,706 — Application of enzyme prodrugs as anti-infective agents
U.S. patent 6,015,567 — HER2 extracellular domain
U.S. patent 5,851,991 — Therapeutic use of the retinoblastoma susceptibility gene product
U.S. patent 5,837,520 — Method of purification of viral vectors
U.S. patent 5,772,997 — Monoclonal antibodies directed to the HER2 receptor
U.S. patent 5,720,954 — Monoclonal antibodies directed to the HER2 receptor
U.S. patent 5,710,255 — Characterization of a novel anti-p110.sup.RB monoclonal antibody
U.S. patent 5,677,171 — Monoclonal antibodies directed to the HER2 receptor
U.S. patent 4,963,354 — Use of tumor necrosis factor (TNF) as an adjuvant
U.S. patent 4,808,402 — Method and compositions for modulating neovascularization
michael, shepard, this, article, multiple, issues, please, help, improve, discuss, these, issues, talk, page, learn, when, remove, these, template, messages, this, biography, living, person, needs, additional, citations, verification, please, help, adding, rel. This article has multiple issues Please help improve it or discuss these issues on the talk page Learn how and when to remove these template messages This biography of a living person needs additional citations for verification Please help by adding reliable sources Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page especially if potentially libelous Find sources H Michael Shepard news newspapers books scholar JSTOR March 2020 Learn how and when to remove this template message This biographical article is written like a resume Please help improve it by revising it to be neutral and encyclopedic February 2023 This article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral Please help improve it by replacing them with more appropriate citations to reliable independent third party sources February 2023 Learn how and when to remove this template message Learn how and when to remove this template message H Michael Shepard born 1949 is an American cancer researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award which he shared with Dennis Slamon and Axel Ullrich for their development of Herceptin 1 H Michael ShepardAlma materUniversity of California DavisIndiana UniversityKnown forCo development of HerceptinAwardsLasker DeBakey Clinical Medical Research Award 2019 Contents 1 Education and career 2 Development of Herceptin 3 Other activity 4 Patents 5 References 6 External linksEducation and career editShepherd holds a bachelor s degree from the University of California Davis and a Ph D from Indiana University Dr Shepard was a Damon Runyon Cancer Research Foundation Fellow at Indiana University His introduction to biotechnology came when he joined Genentech in 1980 Following Genentech he has been a Founder or Principal in several biotech companies These include Canji Inc NewBiotics Receptor Biologix and Halozyme Development of Herceptin editFollowing Ullrich s characterization of the HER2 protooncogene Shepard collaborated with Ullrich and Slamon to explore possible links to breast cancer Slamon discovered along with other colleagues in the field that HER2 overexpression in breast cancer predicts shorter survival However a lot of proteins are overexpressed in cancer cells and correlate with shorter survival Therefore the remaining question was Is the overexpression of HER2 a significant driver in tumor progression and how does this work Shepard and Hudziak discovered that too much HER2 made tumor cells grow better Then made a key discovery about how HER2 can cause resistance to immune cell killing of tumor cells Overexpression of HER2 makes cells resistant to killing by macrophages which are the first line of defense against cancer This work was done in collaboration with Dr Hans Schreiber at the University of Chicago Shepard and colleagues at Genentech Paul Carter Gail Lewis then invented Herceptin the first monoclonal antibody that blocks a cancer causing protein and developed it into a life saving therapy for women with breast cancer The innovation reduces the risk of recurrence and extends survival time for patients with metastatic as well as early stage disease Every year more than 50 000 women in the US are diagnosed with the type of breast cancer that the drug attacks and over 2 3 million individuals have received the treatment since it became available Other activity editShepard has made seminal contributions to gene therapy of cancer to tumor suppressor gene targeted small molecule therapeutics and to drugs which target the tumor extracellular matrix He continues his work now expanding successful treatment paradigms used in cancer to approach inflammatory and autoimmune diseases Shepard also consults for biopharma companies on how to develop meaningful biomarkers that will speed drug development Education is another of Dr Shepard s passions and he gives lectures meant to teach stimulate excite and give hope to interested scientists and students and to cancer patients who need to more about how the disease works Dr Shepard has co authored many peer reviewed publications and patents Patents editU S patent 7 138 388 Methods to treat autoimmune and inflammatory conditions U S patent 7 105 156 Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells U S patent 6 946 259 Compositions and methods for treating cells having double minute DNA U S patent 6 683 061 Enzyme catalyzed therapeutic activation U S patent 6 551 585 Use of tumor necrosis factor as an adjuvant U S patent 6 495 553 Methods and compositions for overcoming resistance to biologic and chemotherapy U S patent 6 399 063 Monoclonal antibodies directed to the HER2 receptor U S patent 6 387 371 Monoclonal antibodies directed to the HER2 receptor U S patent 6 348 352 Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene U S patent 6 339 151 Enzyme catalyzed therapeutic agents U S patent 6 333 169 HER2 extracellular domain U S patent 6 331 524 Organ specific targeting of cationic amphiphile DNA complexes for gene therapy U S patent 6 245 750 Enzyme catalyzed therapeutic agents U S patent 6 165 464 Monoclonal antibodies directed to the HER2 receptor U S patent 6 159 706 Application of enzyme prodrugs as anti infective agents U S patent 6 015 567 HER2 extracellular domain U S patent 5 851 991 Therapeutic use of the retinoblastoma susceptibility gene product U S patent 5 837 520 Method of purification of viral vectors U S patent 5 772 997 Monoclonal antibodies directed to the HER2 receptor U S patent 5 720 954 Monoclonal antibodies directed to the HER2 receptor U S patent 5 710 255 Characterization of a novel anti p110 sup RB monoclonal antibody U S patent 5 677 171 Monoclonal antibodies directed to the HER2 receptor U S patent 4 963 354 Use of tumor necrosis factor TNF as an adjuvant U S patent 4 808 402 Method and compositions for modulating neovascularizationReferences edit 2019 Winners 2019 Retrieved 8 November 2021 External links editReceptor Biologix Alpert Foundation Retrieved from https en wikipedia org w index php title H Michael Shepard amp oldid 1203898028, wikipedia, wiki, book, books, library,
